2024
Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030.
Nader Marta G, Chu X, Mukhopadhyay S, Abramson V, Brufsky A, Stringer-Reasor E, Dent S, Traina T, Carey L, Rimawi M, Specht J, Miller K, Santa-Maria C, Dasgupta T, Binboğa Kurt B, Tayob N, Krop I, Tung N, Schnitt S, Mayer E. Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030. Journal Of Clinical Oncology 2024, 42: 555-555. DOI: 10.1200/jco.2024.42.16_suppl.555.Peer-Reviewed Original ResearchTriple negative breast cancerTumor-infiltrating lymphocytesArea under the curveEvaluation of tumor-infiltrating lymphocytesCore needle biopsyNeoadjuvant chemotherapyPredictive of responseOdds ratioReceiver operating characteristicImmune microenvironmentEarly-stage triple negative breast cancerPre-treatment core needle biopsyPrediction of response to NACBaseline tumor-infiltrating lymphocytesEvaluate tumor-infiltrating lymphocytesStromal tumor-infiltrating lymphocytesResponse to NACTumor-infiltrating lymphocyte scoresResponse to neoadjuvant chemotherapyImmune responseCombined immune responseNegative breast cancerH&E-stained slidesCell cycle aberrationsCell cycle signature
2019
The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy
Waks AG, Stover DG, Guerriero JL, Dillon D, Barry WT, Gjini E, Hartl C, Lo W, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, Yang F, Sullivan A, Danaher P, Brauer HA, Osmani W, Lipschitz M, Hoadley KA, Goldberg M, Perou CM, Rodig S, Winer EP, Krop IE, Mittendorf EA, Tolaney SM. The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy. Clinical Cancer Research 2019, 25: 4644-4655. PMID: 31061067, PMCID: PMC6677598, DOI: 10.1158/1078-0432.ccr-19-0173.Peer-Reviewed Original ResearchConceptsStromal tumor-infiltrating lymphocytesImmune microenvironmentNeoadjuvant chemotherapyPD-L1Breast cancerHormone receptor-positive breast cancerBreast tumorsHormone receptor-positive/HER2-negative breast cancerHER2-negative breast cancerDistant metastasis-free survivalReceptor-positive breast cancerImmunotherapy-based approachesPAM50 intrinsic subtypesCheckpoint inhibitor therapyPD-L1 stainingTumor-infiltrating lymphocytesMetastasis-free survivalMacrophage-targeted therapiesRole of macrophagesPreoperative chemotherapyStandard chemotherapyInhibitor therapyResidual diseaseMyeloid signaturePoor responseThe immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial
Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Annals Of Oncology 2019, 30: 575-581. PMID: 30753274, PMCID: PMC8033534, DOI: 10.1093/annonc/mdz047.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBiomarkers, TumorBreastBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMastectomyMiddle AgedPaclitaxelReceptor, ErbB-2TrastuzumabTumor BurdenTumor MicroenvironmentConceptsHER2-positive breast cancerSmall HER2-positive breast cancersImmune gene signaturesBreast cancerImmune profileAPT trialPD-L1Immune markersImmune microenvironmentSmall HER2-positive tumorsStromal PD-L1 expressionNode-negative breast cancerCell signatureGene signatureHuman epidermal growth factor receptorStromal PD-L1PD-L1 expressionHistological grade 2Luminal B tumorsB cell signaturesBreast cancer trialsHER2-positive tumorsImmune cell signaturesBasal-like tumorsHistological grade 1
2017
Immune biomarkers and treatment (tx) outcome in hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus bevacizumab (bev).
Waks A, Barry W, Gjini E, Dillon D, Rodig S, Brock J, Baltay M, Savoie J, Stover D, Winer E, Krop I, Tolaney S. Immune biomarkers and treatment (tx) outcome in hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus bevacizumab (bev). Journal Of Clinical Oncology 2017, 35: e12134-e12134. DOI: 10.1200/jco.2017.35.15_suppl.e12134.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesTPD-L1Miller-PaynePathologic responseImmune biomarkersHormone receptor-positive breast cancer patientsReceptor-positive breast cancer patientsPanCancer Immune Profiling PanelResidual cancer burden scorePathologic complete responsePD-L1 expressionBreast cancer patientsPD-L1 scoresImmune Profiling PanelImportant clinical implicationsPreoperative chemotherapyComplete responseProspective trialTumor-immune interactionsBurden scoreCancer patientsImmune microenvironmentUnadjusted analysesTumor gradeTreatment outcomes
2016
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
Incio J, Tam J, Rahbari NN, Suboj P, McManus DT, Chin SM, Vardam TD, Batista A, Babykutty S, Jung K, Khachatryan A, Hato T, Ligibel JA, Krop IE, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Shibuya M, Carmeliet P, Soares R, Duda DG, Jain RK, Fukumura D. PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. Clinical Cancer Research 2016, 22: 2993-3004. PMID: 26861455, PMCID: PMC4911258, DOI: 10.1158/1078-0432.ccr-15-1839.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBreast NeoplasmsDiet, High-FatFemaleGlucoseHumansHypoglycemic AgentsMacrophagesMetforminMiceMice, Inbred C57BLMice, KnockoutMice, ObeseNeovascularization, PathologicObesityPancreatic NeoplasmsPlacenta Growth FactorPrognosisSignal TransductionVascular Endothelial Growth Factor Receptor-1ConceptsMouse modelTumor progressionTumor-associated macrophage recruitmentDiet-induced obese mouse modelTumor angiogenesisVEGFR-1Breast cancer mouse modelRole of PlGFBreast cancer patientsTumor immune microenvironmentObese mouse modelPlacental growth factorWild-type C57BL/6Addition of metforminHigh-fat dietTumor immune environmentCancer mouse modelReceptors VEGFR-1Breast cancer modelBreast cancer progressionAntitumor immunityTAM infiltrationImmune environmentInsulin levelsImmune microenvironment